Earnings Bonanza: Exclusive Stock Alert Inside!

Earnings Alert. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Ad [Detecting Cancer in 1.5 Seconds: Early Investment Opportunity]( [Learn more about how this could transform the multi-billion dollar diagnostic market.]( --------------------------------------------------------------- March 6, 2024 (Earnings Report) From the desk of the Editor Dear Reader, We just identified several stocks that are expected to release earnings very soon. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements. --------------------------------------------------------------- Sponsor Ad [Is Gold Really Boring?]( investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. [See why this could be a huge untapped gold investing opportunity.]( --------------------------------------------------------------- [Arcturus Therapeutics Holdings Inc.]( Symbol: [ARCT]( Recent Price: $37.56 Average Analyst Price Target: $74.80 (99.15%) Market Cap: $1.00B Last Year's EPS: $-1.98 Consensus EPS Forecast: $-1.79 Expected Earnings Date: Mar 07, 2024 Recent Analyst Action: Yigal Nochomovitz, analyst at Citi, reiterates coverage on [Arcturus Therapeutics Holdings Inc. (ARCT)]( in the Healthcare sector with a Buy rating and a price target of $48 (4 weeks ago). [TipRanks.com]( also reports that [Arcturus Therapeutics Holdings Inc.]( currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $74.80 . The target pricing ranges from a high forecast of $81 down to a low forecast of $140. [Arcturus Therapeutics Holdings Inc. (ARCT)](’s last closing price was $37.56 which would put the average price target at 99.15% upside. Here are 3rd party ratings for [ARCT](: - TipRanks.com: Buy - TradingView.com: Neutral - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 32% (80 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Ad [#1 Stock for Energy Crisis (Buy Now for Just $8)]( the world suffers an oil shock… And gas prices rip higher… One tiny company could have the answer to the global energy crisis. It’s using AI to crack open the largest untapped energy source on the planet… 5X larger than the biggest oil field on Earth. [Act fast, this $8 stock could be moments away from appreciating considerably.]( --------------------------------------------------------------- [Poseida Therapeutics, Inc.]( Symbol: [PSTX]( Recent Price: $3.48 Average Analyst Price Target: $14.00 (302.30%) Market Cap: $332.77M Last Year's EPS: $-0.32 Consensus EPS Forecast: $-0.29 Expected Earnings Date: Mar 07, 2024 Recent Analyst Action: Sami Corwin, analyst at William Blair, reiterates coverage on [Poseida Therapeutics, Inc. (PSTX)]( in the Healthcare sector with a Buy rating (2 months ago). [TipRanks.com]( also reports that [Poseida Therapeutics, Inc.]( currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $14.00 . The target pricing ranges from a high forecast of $20 down to a low forecast of $10. [Poseida Therapeutics, Inc. (PSTX)](’s last closing price was $3.48 which would put the average price target at 302.30% upside. Here are 3rd party ratings for [PSTX](: - TipRanks.com: Buy - TradingView.com: Sell - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 32% (80 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Ad [URGENT: Don't risk your retirement]( looming recession, inflation, unpayable debt, a failing dollar, and a crumbling housing market all put your savings in extreme risk. Protect your retirement with this free guide that shows you how to guard your money against economic downturns with gold. Take action NOW, before it’s too late, Download your free guide and see for yourself why gold is the #1 safe haven for smart investors. [Protect your retirement with this free gold guide]( --------------------------------------------------------------- [Gevo, Inc.]( Symbol: [GEVO]( Recent Price: $0.79 Average Analyst Price Target: $5.73 (625.74%) Market Cap: $190.72M Last Year's EPS: $-0.06 Consensus EPS Forecast: $-0.06 Expected Earnings Date: Mar 07, 2024 Recent Analyst Action: Dushyant Ailani, analyst at Jefferies, reiterates coverage on [Gevo, Inc. (GEVO)]( in the Basic Materials sector with a Hold rating and a price target of $1 (1 month ago). [TipRanks.com]( also reports that [Gevo, Inc.]( currently has 3 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $5.73 . The target pricing ranges from a high forecast of $2.2 down to a low forecast of $1. [Gevo, Inc. (GEVO)](’s last closing price was $0.79 which would put the average price target at 625.74% upside. Here are 3rd party ratings for [GEVO](: - TipRanks.com: Buy - TradingView.com: Strong Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Sell, Bottom 33% (168 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- [TORM plc]( Symbol: [TRMD]( Recent Price: $33.39 Average Analyst Price Target: $34.16 (2.30%) Market Cap: $3.01B Last Year's EPS: $2.14 Consensus EPS Forecast: $1.32 Expected Earnings Date: Mar 07, 2024 Recent Analyst Action: Jonathan Chappell, analyst at Evercore ISI, reiterates coverage on [TORM plc (TRMD)]( in the Energy sector with a Buy rating and a price target of $42 (1 month ago). [TipRanks.com]( also reports that [TORM plc]( currently has 3 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $34.16 . The target pricing ranges from a high forecast of $42 down to a low forecast of $25.47. [TORM plc (TRMD)](’s last closing price was $33.39 which would put the average price target at 2.30% upside. Here are 3rd party ratings for [TRMD](: - TipRanks.com: Buy - TradingView.com: Neutral - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: buy - Zacks.com: n/a, n/a [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Ad [GPT-4 vs. X.AI: The Race of the New AI Giants]( smart money investors all know AI is the wave of the future and could mean huge profits for anyone involved. AI has been called the biggest new industry of the 21st century. Experts are projecting it will be worth a staggering $80 trillion over the next 10 years. And right now, Chief Investment Strategist Adam O’Dell is revealing his favorite X.AI stock you should check out today. [Click here to see the full story now.]( --------------------------------------------------------------- [Broadcom Inc.]( Symbol: [AVGO]( Recent Price: $1,342.75 Average Analyst Price Target: $1,460.00 (8.73%) Market Cap: $622.26B Last Year's EPS: $10.54 Consensus EPS Forecast: $10.98 Expected Earnings Date: Mar 07, 2024 Recent Analyst Action: Hans Mosesmann, analyst at Rosenblatt Securities, reiterates coverage on [Broadcom Inc. (AVGO)]( in the Technology sector with a Buy rating and a price target of $1500 (2 days ago). [TipRanks.com]( also reports that [Broadcom Inc.]( currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $1,460.00 . The target pricing ranges from a high forecast of $1550 down to a low forecast of $1250. [Broadcom Inc. (AVGO)](’s last closing price was $1,342.75 which would put the average price target at 8.73% upside. Here are 3rd party ratings for [AVGO](: - TipRanks.com: Buy - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Sell, Bottom 21% (200 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Ad [Gold Could Be Heading for Record Highs - But How to Play It?]( to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. [See this little-known way to play in the rising gold market.]( --------------------------------------------------------------- And there you have it--- Stocks expected to release earnings soon... Sincerely, The Editor, MarketInsidersPress.com MarketInsidersPress.com Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be a third party advertisements where the advertiser is paying per click, per lead or per sale and are not endorsed or warranted by our staff or company. Sandpiper Marketing Group, LLC is also being compensated by Summit Publishing Group and Investing Trends up to three dollars per click and may exceed twelve thousand, five hundred dollars per week for placement of specific advertisements contained in this newsletter. Sandpiper Marketing Group, LLC and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. Sandpiper Marketing Group, LLC nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Sandpiper Marketing Group, LLC to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. [If you are not a human, click here.]( By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. This is part of your free subscription to MarketInsidersPress.com MarketInsidersPress.com part of Sandpiper Marketing Group, LLC 165 Lockerbie Lane | Mooresville NC | 28115 MarketInsidersPress.com part of Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy | Unit 4 | Mount Mourne | NC | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software